Vaxxinova US, formerly Epitopix, plans $10 million to $20 million investment for expansion in Willmar

Date Published11/15/2022
Author NameJennifer Kotila
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Vaxxinova US
Parent companyVaxxinova GmbH
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Year reshoring announced:2022
Capital investment ($):20
Country(ies) from which reshored:Netherlands
City reshored to:Willmar
State(s) reshored to:MN
If relevant, work nearshored to:-
Product(s) reshoredveterinary vaccines
What domestic positive factors made reshoring more attractive?Government Incentives
Government Incentive dollar amount:$1.3 million grant from the state
Find Reshoring Articles